Article

Pathogenesis and therapy of focal segmental glomerulosclerosis: an update

Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
Pediatric Nephrology (Impact Factor: 2.88). 11/2010; 26(7):1001-15. DOI: 10.1007/s00467-010-1692-x
Source: PubMed

ABSTRACT Focal and segmental glomerulosclerosis (FSGS) is an important cause of steroid-resistant nephrotic syndrome in adults and children. It is responsible for 5-20% of all cases of end-stage kidney disease (ESKD) in the United States. The pathogenesis of FSGS has not been fully elucidated; however, data from molecular studies of familial cases in the last two decades suggest that FSGS is a defect of the podocyte. The therapeutic agents available for treatment of FSGS are not very effective and only a small percentage of affected individuals will achieve complete remission. Recent data from molecular biology and molecular genetics has provided insight into the mechanisms of action of old agents and also identification of other novel therapeutic targets. This review focuses on recent advances in the molecular pathogenesis of FSGS and currently available therapeutic agents as well as potential novel therapies.

Download full-text

Full-text

Available from: Peter J Lavin, Jun 29, 2015
0 Followers
 · 
257 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since glomerular sclerosis frequently accompanies various glomerular diseases at the end stages, it is challenging to differentiate ubiquitous biological processes underlying this pathology from those critically involved in specific diseases. Furthermore, in-depth proteomic profile of human glomerular sclerosis remains limited. In this study, human glomeruli with intermediate (i-GS) and advanced (GS) sclerotic lesions, which were excluded from specific renal diseases and assumed to be aging-related, were laser captured from macroscopically normal cortex distant from urological carcinoma, and subjected to label-free quantitative proteomic analysis. We explicate an evident increase of membrane attack complex in i-GS and GS with an up-going tendency, which is accompanied by increasing of inhibitory regulators of alternative and terminal pathways. GO annotation and IPA pathway analysis agree to these results. Proteomic findings are validated by immunohistochemical studies which indicate that alternative and terminal pathways are positively involved in the glomerular sclerosis seen in distinct renal diseases. Furthermore, proteomic analysis also demonstrates remarkable increases of complement factor B in GS and TGF-ß1 in both GS and i-GS. Identification of complement factor B implicates that on-site activation of alternative pathway may occur in injured glomeruli and stepwise increase of TGF-ß1 suggests its contribution to the progression of glomerulosclerosis. This study provides in-depth quantitative proteomic profiles of human glomeruli with intermediate and advanced sclerotic lesions. It reveals that the over-expression of alternative and terminal pathway components is significantly involved in human glomerulosclerosis seen in distinct renal diseases. Proteomic identification of the increased TGF-ß1 provides supporting evidence for the role of podocyte apoptosis leading to human glomerulosclerosis. Copyright © 2015 Elsevier B.V. All rights reserved.
    Journal of proteomics 03/2015; 123. DOI:10.1016/j.jprot.2015.03.024 · 3.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. To assess whether high-molecular-weight proteins excretion predicts outcome and therapy-responsiveness in patients with FSGS and nephrotic syndrome. Research Design and Methods. Thirty-eight patients measured at biopsy fractional excretion of IgG (FEIgG) and urinary α 2-macroglobulin/creatinine ratio ( α 2m/C). Low and high risk groups were defined by cutoffs assessed by ROC analysis. In all patients first-line therapy was with steroids alone or in combination with cyclophosphamide. Results. α 2m/C and FEIgG were correlated with segmental sclerosis (r = 0.546; r = 0.522). Twenty-three patients (61%) entered Remission and 9 (24%) progressed to ESRD. Comparing low and high risk groups, by univariate analysis remission was predicted by FEIgG (77% versus 25%, P = 0.016) and α 2m/C (81% versus 17%, P = 0.007) and ESRD at best by FEIgG (0% versus 75%, P < 0.0001) and α 2m/C (4% versus 67%, P < 0.0001). By multivariate analysis FEIgG was the only independent predictor of remission and α 2m/C the most powerful predictor of ESRD. Low and high risk groups of FEIgG and α 2m/C in combination had very high predictive value of sustained remission and ESRD in response to therapy. Conclusions. FEIgG and α 2m/C are powerful predictors of outcome and responsiveness to steroids and cyclophosphamide; their predictive value, if validated in prospective studies, may be useful in clinical practice suggesting first-line alternative treatments in high risk patients.
    01/2013; 2013:941831. DOI:10.1155/2013/941831
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A 73-year-old man with systemic edema and oliguria, which appeared within several days, was referred to our hospital. Urinalysis showed massive proteinuria, and the blood examination results indicated nephrotic syndrome. Renal biopsy revealed the existence of focal segmental glomerulosclerosis (FSGS), and further investigation indicated that the microscopic features were consistent with the “cellular variant (CELL)” according to the Columbia Classification. After biopsy, 40 mg per day of oral prednisolone was administered daily. With steroid therapy, the abnormal values of the blood examination and urinalysis gradually reached normal, and complete remission was achieved on day 43 after initiating steroid administration. Microscopic investigation by follow-up renal re-biopsy revealed several sclerosing glomeruli; however, other intact glomeruli had no endothelial proliferation, which is a hallmark of CELL. The patient was discharged after biopsy and observed as an outpatient, with maintenance of clinical remission.
    11/2012; 1(2). DOI:10.1007/s13730-012-0017-2